FDA Approves First Drug to Prevent Graft Versus Host Disease

SILVER SPRING, Md., Dec. 15, 2021 -- (Healthcare Sales & Marketing Network) -- Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), a condition that occurs w... Biopharmaceuticals, FDA Bristol Myers Squibb, Orencia, abatacept, Graft Versus Host
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news